The TaqMan PCR classifies six types of Trypanosoma cruzi and was validated on a large international set of samples.
The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.
The firm is pursuing CE-IVD clearance of the new platform populated with a menu of its MGB assays.
The companies' first offering is expected to be a multiplex respiratory disease panel.
The test adds to a growing menu of approved assays for the cobas 4800 system.
The new Riken president outlines some of his plans for the institute.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.